載入...
The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo
Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 15% of all pediatric cancer-related deaths. New therapies are needed to improve outcomes for children with high-risk and relapsed tumors. Inhibitors of the RET kinase and the RAS-MAPK pathway have previously been...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6824878/ https://ncbi.nlm.nih.gov/pubmed/31695841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27259 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|